首页> 美国卫生研究院文献>Human Vaccines Immunotherapeutics >The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5–15 y after primary immunization; China 2009–2010
【2h】

The effects of different dosage levels of hepatitis B vaccine as booster on anti-HBs-negative children 5–15 y after primary immunization; China 2009–2010

机译:初次免疫后5-15年不同剂量水平的乙肝疫苗作为加强剂对抗HBs阴性儿童的影响;中国2009–2010年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The changes in lgG antibody levels to hepatitis B surface antigen (HBsAg) and in antibody to HBsAg (anti-HBs) seroconversion rates due to different dosages of hepatitis B vaccine (HepB) were compared in 2106 children. Children who had been previously vaccinated as infants with HepB were revaccinated at 5–15 y of age, after which the antibody titers were determined. After the first booster dose, the anti-HBs seroconversion rate (defined as an anti-HBs ≥10 mIU/ml) with 10 μg of HepB (93.6%) was significantly greater than the rate with 5 µg of HepB (90.3%) (P < 0.05); the anti-HBs seroconversion rate in 10–15-y-old boys vaccinated with 10 μg of HepB (90.9%) was significantly greater than the rate with 5 µg of HepB (84.3%) (P < 0.05). The anti-HBs seroconversion rates after the third booster dose with 5 or 10 μg of HepB were greater than those after the first booster dose (99.6% and 99.7%, vs. 90.3% and 93.6%, P < 0.05); as was the corresponding GMTs (658 ± 4 mIU/ml and 2599 ± 3 mIU/ml, vs. 255 ± 11 mIU/ml and 877 ± 11 mIU/ml [P < 0.05]). The immunization effects of booster vaccination with 3 doses of HepB with 5 or 10 µg are effective; a single booster dose with 10 µg of HepB for 10–15-y-old boys and with 5 or 10 µg of HepB for 5–9 y old boys and for 5–15-y-old girls are effective in generating protective antibody against HBV; however, for anti-HBs-negative children after a single dose of booster, 3 doses are needed.
机译:比较了2106名儿童由于不同剂量的乙型肝炎疫苗(HepB)而产生的针对乙型肝炎表面抗原(HBsAg)的IgG抗体水平和针对HBsAg的血清转化率(抗HBs)的变化。以前曾接种过HepB婴儿的儿童在5-15岁时进行了疫苗接种,之后确定了抗体效价。首次加强剂量后,含10μgHepB的抗HBs血清转化率(定义为抗HBs≥10 mIU / ml)(93.6%)显着高于含5μgHepB的抗HBs血清转化率(90.3%)( P <0.05);接种10μgHepB的10-15岁男孩的抗HBs血清转化率(90.9%)显着高于5μgHepB的抗HBs血清转化率(84.3%)(P <0.05)。在第3次加强剂量后加5或10μgHepB的抗HBs血清转化率高于第一次加强剂量后(99.6%和99.7%,相对于90.3%和93.6%,P <0.05);以及相应的GMT(658±4 mIU / ml和2599±3 mIU / ml,而255±11 mIU / ml和877±11 mIU / ml [P <0.05])。 3剂量的HepB的5或10 µg加强疫苗的免疫效果是有效的。对于10–15岁的男孩,单次加强剂量含10 µg HepB,对于5–9岁的男孩和5–15岁的女孩,含5或10 µg HepB可有效产生针对乙肝病毒但是,对于单剂量加强免疫后抗HBs阴性的儿童,需要3剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号